





Program	Indications	Lead selection	IND-enabling activities	Phase 1	Phase 1b	Phase 2
Cabiralizumab* (FPA008) CSF-1R antibody 	Pancreatic cancer (combination with <i>Opdivo</i> [®] and chemo)					
	Multiple tumor settings (combination with <i>Opdivo</i> [®])					
	ADVISE trial (combination with <i>Opdivo</i> [®])					
	Pigmented villonodular synovitis (PVNS)					
Bemarituzumab (FPA144**) FGFR2b antibody 	Gastric cancer FIGHT Phase 1/3 trial (with chemo)					
	Bladder cancer					
FPA150 B7-H4 antibody	Multiple tumor settings					
FPT155 CD80-Fc	Multiple tumor settings					
TIM-3 antibody* 	Multiple tumor settings					
I-O antibody* 	Multiple tumor settings					
Novel I-O Biologics	Multiple tumor settings					